3 Stocks To Watch After Fed Meeting At Jackson Hole, Wyoming

CORAL GABLES, FL / ACCESSWIRE / August 24, 2017 / On Wednesday (8/23), The Fed met at their annual meeting in Jackson Hole, Wyoming as conviction for another U.S. rate hike before the end of 2017 has faded due to the concern of weak inflation. The minutes that were published on Wednesday (8/23) also signaled the Fed was ready to start cutting its $4.2 trillion portfolio of Treasury bonds and mortgage-backed securities. The Fed left interest rates unchanged. With that being said, here are three stocks to watch after the Fed’s meeting in Jackson Hole, Wyoming: Medical Imagining Corp. (MEDD), 22nd Century Group, Inc. (XXII) and Biostage, Inc. (BSTG).

Medical Imaging Corp. (MEDD) a provider of comprehensive medical imaging services to patients and client hospitals in the U.S. and Canada, announced on Monday (8/21) that they have upgraded their CT machine at their Naples, FL location.

“Our Naples CT business has been growing throughout 2017, so it was important to have the software installed to meet the new federal standards and ensure that we had a stronger and newer CT machine with greater up time as we approach the start of our busy season this fall,” stated Mitch Geisler, CEO. “The machine has now been installed and we can resume scanning CT patients this week.”

In the last week of trading, (MEDD) has seen an increase in trading activity resulting in an 18.40% increase in price per share from lows on August 14th at $0.0701 to Tuesday’s (8/22) closing price at $0.083. The stock is currently trading between a price range of $0.08-$0.10. For Free Report on MEDD, Click Here.

22nd Century Group, Inc. (XXII) a plant technology biotech company that is focused on tobacco harm reduction and marijuana research has been seeing an increase in price per share since the start of this trading week. (XXII) Is up 13.86% from lows on Monday at $2.02 to pre-market highs on Thursday morning at $2.30. The company recently announced that a growing number of independent scientists specializing in tobacco harm reduction are publicly proclaiming the FDA’s recent plan to reduce nicotine to non-addictive levels in cigarettes.

“More than $100 Million of independent research has demonstrated that 22nd Century’s proprietary Very Low Nicotine tobacco could save many millions of lives and will prevent future generations of young people from becoming addicted to cigarettes,” stated Henry Sicignano, III, President and CEOof 22nd Century Group. “22nd Century’s technology is proven. The FDA plan is already feasible. The time to implement a mandate of Very Low Nicotine tobacco in all combustible cigarettes sold in the United States has arrived.”

Biostage, Inc. (NASDAQ: BSTG) a biotechnology company that develops bioengineered organ implants to treat cancer, and other diseases is up 14% in pre-market trading on Thursday reaching highs of $0.38. Over the course of this trading week (BSTG) is up 51.39% from lows of $0.251 on Tuesday (8/22) to highs on Thursday of $0.38. The company recently announced Q2 2017 financial results on August 14th.

“In summary, the financial and clinical validation of the company has now created a funding runway through 2018,” reported Jim McGorry, CEO of Biostage. “This is a material moment for Biostage as the Company has reduced its technical risk and is pursuing a speed to market strategy. We are delighted to extend Biostage’s horizon with a key investment from a long-term strategic investor.”

For free up to the minute financial news updates, text keyword HFNEWS to 474747.

About HeraldFinance.com

HeraldFinance.com (“HF”) is owned by MAD Media Publishing LLC, a Nevada corporation. HF produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. HF has not been compensated: an affiliate company of HF, MIDAM VENTURES LLC, has been compensated $150,000 by a non-affiliate 3rd party for a period beginning 8/8/2017 and ending 9/7/2017 to publicly disseminate information about MEDD. We own zero shares.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither HF nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.HeraldFinance.com/.

NO WARRANTY

HF, the Author, and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect, or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

Contact:

editor@heraldfinance.com

SOURCE: HeraldFinance.com

ReleaseID: 473656